• Publications
  • Influence
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
PURPOSE Evaluate response rate, duration of response (DOR), time-to-progression (TTP), overall survival (OS), and safety of bortezomib treatment in patients with relapsed or refractory mantle cellExpand
  • 657
  • 26
  • PDF
The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts.
BACKGROUND No firm data are available on the natural history of idiopathic thrombocytopenic purpura (ITP) or on mortality rates or frequency of major bleeding episodes associated with this condition.Expand
  • 347
  • 8
  • PDF
NCCN clinical practice guidelines in oncology: multiple myeloma.
  • 238
  • 8
Colony-stimulating factors for febrile neutropenia during cancer therapy.
A 55-year-old, previously healthy woman received a diagnosis of diffuse large-B-cell lymphoma after the evaluation of an enlarged left axillary lymph node obtained on biopsy. She had beenExpand
  • 108
  • 7
  • PDF
Cancer- and chemotherapy-induced anemia.
Anemia is prevalent in 30% to 90% of patients with cancer. Anemia can be corrected through either treating the underlying cause or providing supportive care through transfusion with packed red bloodExpand
  • 114
  • 6
  • PDF
Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission.
BACKGROUND Consolidation chemotherapy, autologous hematopoietic cell transplantation (HCT) and allogeneic HCT represent potential treatment alternatives for post-remission therapy in adult acuteExpand
  • 48
  • 4
Multiple myeloma. Clinical practice guidelines in oncology.
: Although multiple myeloma is sensitive to both chemotherapy and radiation therapy, it remains incurable at present. However, treatment algorithms (based on published data and clinical experience)Expand
  • 48
  • 3
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple
Patients with multiple myeloma (MM) with mutated RAS are less likely to respond to chemotherapy and have a shortened survival. Therefore, targeting RAS farnesylation may be a novel approach toExpand
  • 101
  • 3
Farnesyltransferase inhibitor FTI‐R115777 is well tolerat ed, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple
Patients with multiple myeloma (MM) with mutated RAS are less likely to respond to chemotherapy and have a shortened survival. Therefore, targeting RAS farnesylation may be a novel approach toExpand
  • 96
  • 3
Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update
To provide an update on recent revisions to Evaluation of Genomic Applications in Practice and Prevention (EGAPP) methods designed to improve efficiency, and an assessment of the implications ofExpand
  • 43
  • 3
  • PDF